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ABSTRACT 
 
The aim of this study was to investigate the role of paclitaxel on RAB family of genes  
in primary breast cancer cell lines. The cancer breast cells obtained from 40 women during 
mastectomy were used to address this issue.  
The group included patients with intraductal breast cancer – lesions in I or II 
advancement level by TNM classification and G1-G2 by Bloom classification. (tumor 
dimensions up to 2.0 cm without metastases to lymph nodes). Cytostatic drugs before 
surgery were not administered to these patients.  
The cultures were conducted in 25 cm2  plastic containers at RPMI medium with 
addiction of 10% fetal bovine serum (FBS) at the standard conditions. After reaching 
concentration levels of 10 000/ml of the cells, the cultures were treated with 60 ng/ml and 
300 ng/ml doses of paclitaxel.  The concentrations were calculated in relation to therapeutic 
doses of paclitaxel, applied in polytherapy in patients with breast cancer. The cell cultures 
untreated for cytostatic were used as a control group. To these cultures, 5% DMSO was 
administered.   
Analysis was conducted for RAB family of genes: RAB3D, RAB5B, RAB5C, RAB7, 
RAB7L1, RAB9P1,  RAB10. RAB11A,   RAB311B, RAB13, RAB18, RAB22A, RAB23, 
RAB26, RAB27A, RAB27B,  RAB28, RAB30, RAB31, RAB33A,  RAB3D6, RAB 38, RABL2B  
Total RNA was extracted from the harvest control group and the treated cells, and 
this was followed by cDNA synthesis, which was used for hybridization assays using arrays. 
A lower dose of paclitaxel (60 ng/ml) treatment resulted in an increase (2-4 fold- statistically 
significant), whereas a higher dose (300 ng/ml) caused a decrease (2-fold – statistically 
insignificant) in expression of examined oncogenes, compared to that of the control group. 
 
N
at
ur
e 
Pr
ec
ed
in
gs
 : 
hd
l:1
01
01
/n
pr
e.
20
11
.6
22
7.
1 
: P
os
te
d 
10
 A
ug
 2
01
1
In summary, this data indicates that 60 ng/ml paclitaxel dose induced the RAB gene 
expression in an up-regulated pathway. A higher concentration of cytostatic (300 ng/ml) is a 
toxic dose for primary breast cells in vitro. 
Keywords: breast cancer; paclitaxel; RAB family genes; microarray 
 
INTRODUCTION 
 
  In the metabolism of neoplasm cells, processes involving division and growth play an 
important role. It has been reported that alterations in gene expression involved in the cell 
cycle were also characteristic of an increased activity of genes associated in cell proliferation 
and growth. These changes usually correlate with a decreased expression of genes that 
control growth, division and transcription processes in the cells. Oncogenes play a very 
important role in the transformation of normal cells to neoplastic cells. A significant number of 
these genes encode signaling proteins within the cell.  
Some of these code factors influence cellular growth (sis, int) and growth factor receptors 
(erb-B, fms). In this group, there are known genes which code transcription factors (myb, 
myc, jun, fos), kinases (src,yes, abl, raf, mos), GTP binding proteins (ha-ras, ki-ras, n-ras) 
(1).  
Some of these genes cause the transformation from normal cells to neoplastic cells when 
mutation in their structure occurs.  
BRCA1 belongs to the suppressor genes group, which is an activator of the transcription 
process, involved mainly in the DNA repairing system (2). The genes that belong to this 
group can inhibit or activate cell growth and proliferation in 2 ways. One of them inhibits 
transformation processes when they are not damaged by mutations. The normal function of 
these genes stops cell proliferation. P53 codes protein responsible for phosphorylation 
products of different genes (3). It plays a crucial role in controlling the cell cycle by activating 
more than 30 genes (4,5). P-53 activates genes encoding proteins which can inhibit 
apoptosis. This protein stops the cell cycle in the G1 and G2 phase, which can enable DNA 
repairing.  MDM-2 is the main protein that causes the decrease of p-53 level.  MYC protein is 
responsible for the increased level of p53 and ARF. The active form of P53 can be released 
from the MDM/P53 complex (1). The higher expression of these genes activates proliferation 
processes. The mentioned genes (RAB, ACT, MYC, JUN, FOS) can activate faster growth, 
division of cells and transformation processes. 
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MATERIALS 
 
  The cancer cells were obtained from breast tissues of 40 women with 
histopathologically confirmed breast cancer. The group included patients with intraductal 
breast cancer – lesions in I or II advancement level by TNM classification and G1-G2 by 
Bloom classification. (tumor size up to 2.0 cm without metastases to lymph nodes). There 
patients were not administered any cytostatic drugs before surgery. The primary cultures 
were conducted in 25 cm2  plastic containers at RPMI medium with 10% fetal bovine serum 
(FBS SIGMA), at standard conditions (37°C, 5% CO2, 90% humidity of the air).  
Paclitaxel in 60 ng/ml and 300 ng/ml doses was administered to these cultures after 
achieving concentration of the cells 10 000/ml. The cytostatic concentrations were calculated 
in relation to therapeutic doses of paclitaxel applied in polytherapy in patients with breast 
cancer. The control culture was a suspension of the breast cancer cells without the 
administration of cytostatic treatment. To these cultures 5% DMSO was administered. The 
experiments were conducted in three independent trials for all mentioned groups of cultures.  
Analysis was related to RAB family of genes : RAB3D, RAB5B, RAB5C, RAB7, RAB7L1, 
RAB9P1,  RAB10. RAB11A,   RAB311B, RAB13, RAB18, RAB22A, RAB23, RAB26, 
RAB27A, RAB27B,  RAB28, RAB30, RAB31, RAB33A,  RAB3D6, RAB 38, RABL2B. 
 
METHODS 
 
After an incubation period of 72 hours with two doses of paclitaxel, the cultures were 
homogenized in TRI (SIGMA) solution. RNA (total RNA) obtained from the cultures was 
controlled with the presence of impurities and DNA. It was controlled on a spectrophotometer 
(EPPENDORF).  
Panorama Human Cancer cDNA Labeling and Hybrydyzation Kit; CDLBL-HCN 
(SIGMA-GENOSIS) was used to obtained cDNA from total RNA. The kit included control 
RNA from E. coli  (Panorama Armored RNA E. coli-B 1444 RNA). RNA from E. coli let 
calibrate expression of examined genes in comparison to this gene.  
Water was added to the samples containing 2 µg total RNA (4 µl) and 2 µl control 
RNA Escherichia coli reaching 10.0 µl. Mix (dATP, dGTP, dTTP) and labeled 32P dCTP of 40 
µCi activity , 6 µl reverse transcriptase and solution buffer (4 µl) were added to the samples. 
This mix was incubated at 42 ° C for 2.5 hours. In reverse transcription, the reaction cDNA 
containing labeled 32P cytidine was estimated. Such received and purified cDNA was 
hybridized on the array. The Sigma-Genosis array contained sequences of oncogenes on the 
ground. cDNA was hybridized with the array in the hybridization chamber at 65° C for a 
period of 13 hours. After purifying the array and removing unconnected fragments of cDNA 
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the ground was dried on a sterile blotting and placed in a cassette with a radiosensitive 
ground to collect the activity from points of the array (Screen Imaging K – Bio Rad) for 24 
hours. After radiation of the radiosensitive ground, using a high resolution scanner it was 
scanned (Molecular Imager FX -BioRad) to estimate the picture of the array. Activities from 
the subsequent points of the array were normalized with the expression level of E. coli-B 
genes localized in control points. Statistic analysis was conducted by using program 
Statistica 6.0.  
 
 
RESULTS 
 
Analysis showed that in a group of cells where paclitaxel was administered at a dose 
of 60 ng/ml it caused statistically significant increase expression RAB family of genes in 
comparison to the control group. In the group where paclitaxel was administered at a dose of 
300 ng/ml, a statistically significant decrease expression of the genes coding oncogenes was 
observed in comparison to thecontrol group. 
There was a statistically significant correlation between the gene expression of the 
control group and both mentioned primary breast cell cultures after the administration of 
paclitaxel (P<0.001).  
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Table 1. Expression of RAB family genes. 
 
GENES CONTROL TAXOL 60 TAXOL 300 
RAB3D 8.11 
 
17.43* 
 
6,90 
RAB5B 12.67 
 
48.74* 
 
8.11* 
 
RAB5C 11.28 
 
28.39* 
 
10.46 
 
RAB7 8.97 
 
16.14* 
 
5.83* 
 
RAB7L1 18.39 
 
23.13* 
 
8.96* 
 
RAB9P1 8.25 
 
19.50* 
 
7.20 
 
RAB10 8.70 
 
21.10* 
 
6.84 
 
RAB11A 6.90 
 
27.78* 
 
7.19 
 
RAB11B 13.57 
 
22.13* 
 
8.23* 
 
RAB13 23.95 
 
26.45 
 
10.20* 
 
RAB18 8.46 
 
22.60* 
 
6.66 
 
RAB22A 6.27 
 
22.28* 
 
6.42 
 
RAB23 8.26 
 
25.20* 
 
6.94 
 
RAB26 6.36 
 
24.60* 
 
6.97 
 
RAB27A 16.75 
 
36.51* 
 
11.13* 
 
RAB27B 9.87 
 
17.55* 
 
7.76* 
 
RAB28 8.93 
 
21.10* 
 
9.76 
 
RAB30 7.40 
 
11.92* 
 
6.90 
 
RAB31 6.83 
 
22.94* 6.75 
 
RAB33A 17.76 
 
27.85* 
 
6.76* 
 
RAB36 6.89 
 
20.58* 
 
7.08 
 
RAB38 6.85 
 
22.86* 
 
6.34 
 
RABL2B 13.56 
 
23.17* 
 
7.78* 
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DISCUSSION 
Oncogenes are regulators of transcription. They are factors that inhibit apoptosis and 
create transcription factors. Many of them cooperate with sections of DNA coding regulators 
of gene and promoters.  Products of these genes are responsible for the stimulation of cell 
growth and proliferation. This group presents such analyzed genes as: ASK, PIM1, RAF, 
RAB, RAN, ERBB2-4. A different group is responsible for both proliferation and activation of 
apoptosis. MYC, AP1, TEL belong to such researched genes. In such group of analyzed 
genes, oncogenes, mainly with apoptosis, such as DAXX. MAX, can surface 
 Activation of MYC genes caused by paclitaxel in the cells proves that in researched 
cultures different metabolic pathways can coexistence simultaneously, can stimulate 
induction and inhibition of proliferation. Many products of different genes cooperate with Myc 
in growth and transformation and lead to the inhibited apoptotic characteristic of these 
proteins. Transformation and growth of cancer cells are observed with the increase of 
expression Bcl-2 and MYC gene and decrease expression of BAX (7). The data indicates 
that the influence of paclitaxel induces not only growth of the expression of MYC which leads 
to stimulation., but also antiapoptotic processes which accelerates transformation.  
 Distinct metabolic activation stimulated by Myc and p53 was observed during this 
study. Myc activates P-53 with the participation of P19/ARF protein (6). Myc also stimulates 
these proteins: Bax and Puma. They are connected with apoptosis and activate P-53 (8,9). 
This data indicates that MYC plays a role as an apoptotic activator. This gene can inhibit the 
activity of genes encoding the transcriptor activator MIZ-1 through direct connection with 
them. Myc also regulates processes connected with proliferation (10,11). With regards to the 
apoptosis activation by paclitaxel we should pay attention to the  possibility of the activation  
of these process by means of the P53 gene. Since the product of this gene is connected with 
the control phase of G1/S, it should be noted that paclitaxel is influenced by the regulation of 
the earlier phases of cell cycles. It suggests that sensitivity for paclitaxel is marked not only in 
G2/M phase, but also in G1/S phase. Perhaps the increase response of paclitaxel is 
conected to the inhibition of both these cell cycle phases and caused the inhibition cell 
division in the G1/S phase. On the other hand, in other studies (12) authors did not observe 
any cross resistance between taxanes and drugs influenced in the G1/S phase. It suggested 
that paclitaxel does not influence the first phases of the cell cycle. An investigation conducted 
by Kandioler-Eckersberger (13) showed that a group, of 67 patients with the mutated P53 
gene, responsed to treatment with paclitaxel. There was no correlation found between the 
response to this treatment and the amount of apoptotic cells in patients with normal function 
of the P53 gene. Significant response to paclitaxel was observed in patients with structural 
damage of this gene. These investigations indicate that paclitaxel can regulate the cell cycle 
of G1/S phase and damaged P-53 protein does not influence this process. It seemed that 
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MYC is a gene responsible both for inhibition of cell cycle and apoptosis. The inhibition of 
P21, through activation of the MYC/MIZ-1 complex, plays an important role in this process. 
This process probably plays a key role in switching cell cycle from stopping cell growth to 
apoptosis (14,15). This indicates that genes responsible for stopping growth and apoptotic 
activators should be analyzed separately and not joined in the same group activators of 
programmed cell death. 
 Proliferation processes are activated by (PI3K) phosphatydyloinositolo-3 kinase and 
Rab gene products. Growth factor activates PI3K and Rab gene products which increases 
the activity of PDT/INS(3,4,5)P3 - phosphatydyloinositolo-3,4,5 phosphatase (16) .The aims 
of PDT/INS(3,4,5)P3 are plextrins and FOS. It also leads to releasing AKT from cell 
membranes. AKT is inactivated by PDK-1 in the phosphorylation process (17). AKT is 
responsible for passing to the G2/M phase of the cell cycle. It may also increase the 
expression of AKT in response to the cancer cells blocking the G2/M phase with paclitaxel. In 
cultures, the advantage of apoptotic over proliferation processes was observed. It indicates 
that activation of AKT is not persistent and causes only induction signals to resistance, but 
does not evoke active process. AKT cause inhibition of activity of phosphoinositolo-kinase 
(18). The mentioned kinase activates a great number of different factors, which is the reason 
for excessive proliferation and surviving (19). Additionally, AKT decreases the activity of P21 
and P27 (20). This process can indicate that paclitaxel influences the proliferation processes 
in the G1 phase.  
 Another proliferation factor is the gene ERB2 coding kinase receptor.  
Heterodimerisation ERB2 with other proteins leads to phosphorylation traces of thyrosin and 
creates binding places for SRC proteins. ERB-2 leads to activation proteins such as RAF, 
RAS, RAB, MAPK, cJUN, and ribosomal kinase is responsible for cell growth and 
transformation. In studies on MCF-10A cell line, it was found that the insertion  of the cERB-2 
gene and mutated cH-RAS leads to the induction activity of MDR-1 and P glikoprotein. It 
causes increase of resistance for doxorubicin. Contrary to this excessive activity ERB-2, 3, 4 
and EGF cause alteration in expression of different genes and was a reason for sensitivity to 
treatment. A gene responsible for cell transport is ABL. It also influences the regulation of 
factors connected with transport (21,22). The ABL gene product cooperates with 
microtubules and influences ENA - engaged in intracellular motion (23,24). ABL inhibits 
activation of ENA and lowers the dimerisation factor with KHC (25). It is the reason for the 
increase in activity of kinesin 1 and the acceleration of polymerization  F actin. ABL, 
influenced by the microtubular transport protein, cooperates with their end C plus and 
coordinates the response to actin and microtubules on intracellular signals. It is possible that 
this cooperation is crucial in modeling the intracellular transport. Lowering transport may be 
the reason for the decrease in activity of different cytostatic drugs.  
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 RAF is a transcriptor factor activating in a metabolic pathway RAF/MEK/ERK (26). 
This protein cooperates with different factors such as P21 and MYC. RAF/MEK/ERK 
pathway influences on P glikoprotein which inducts resistance for cytostatic treatment. 
Acceleration of transcription of Bcl-2 in relation to RAF/MEK/ERK results from 
phosphorylation of P-90 and activates CREB. In the next stage, CREB accelerates 
transcription of Bcl-2 by binding with its promotor (27). Mutations in cERB-2 gene lead to 
irregularity in cERB-2 protein what activates RAF. This can be the reason for resistance to 
treatment. Contrary to this process, RAF can inhibit the anti-apoptotic properties product of 
the BCL-2 gene through phosphorylation (28,29). Metabolic pathways increasing proliferation 
and inhibition of apoptosis activated by RAF are in advantage. A great number of pathways, 
activated by the production of the RAB gene, indicates an effectiveness of the proliferation 
process in the tested cells. 
 Another transcription factor, PIM1 joined with CD40, enables connections with TRAF 
2-6 domens and is the reason for surviving and proliferation. It cooperates with NF-kB and 
different kinases such as ERK, cJUN, P38. In cell cultures of FDCP-1 line it causes inhibition 
of apoptosis through inactivation of cytokins, endonucleases and BAX. PIM1 cooperates with 
cMYC which induces the rise of leukemias (30). This protein cooperates with cMYC and 
cMYB, which is the reason for the acceleration of growth and the survival of damaged B 
lymphocytes. Some of the oncogenes accelerate proliferation which can influence the other 
genes and create a positive feedback loop which accelerate transformation and may be the 
reason for the decrease in controlling growth and division of cells in the apoptosis process. It 
seemed that such action exerted PIM1 on the cultures. 
 In the group of oncogenes, genes were identified to play a key role in the activation of 
apoptosis. An example of such gene is DAXX. The main function of this gene is to induce 
morphologic changes in cells. Production of this gene facilitates the release of cytochrom c, 
and activates many caspases (31). An additional function is connected with cytoplasm 
domen of FAS, which induces the rise of FADD domen (32). Product of Daxx gene 
cooperates with many transcription factors: PAX-5, ETS-1 and causes their repression (33). 
This protein induces deacetylation of histone proteins and inhibition of transcription 
processes (34). DAXX, joined with H2a, H2b, H3 and H4 histones, also with histone 
deacetylase - a basal factor, participates in repression of transcription (35). Non-
phosphorylated form of 70 kDa Daxx participates in inhibition of transcription due to 
cooperation with histon deacetylase, DEK proteins and histone coplex (36). The direction of 
these activities is probably dependent on post-transcriptional modification. In some cases it 
can increase the production of the same gene.  
 Oncogenes belong to transcriptor factors that are AP-1 encoded by JUN family 
genes. The AP-1 Group consist of cFOS proteins creating JUN complexes. AP-1 cooperates 
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with transcriptor factors: ATF-2, NFAT. They participate in the proliferation and 
transformation processes. Activation of AP1 is strictly connected with the cooperation of P38. 
P38 which exists in some isoforms (37).  
 RAB proteins are small GTP-ases. They belong to oncogenes coding products 
interacting with proteins located on the inner surface of the cell membrane (38). Their 
expression is regulated by NF-E2. This factor also regulates activity of beta tubulin – a 
protein cooperating with paclitaxel. Paclitaxel can accelerate transcription of genes ranking 
the RAB family. Production of these genes inhibits activity of proteins connected with 
microtubules and the cytoskeletal system of the cell, formed by actin. They control the cell 
cycle and intracellular transport in cytoplasm. In the nucleus, they participate in forming 
nucleosomes and organize the mitotic spindle. They also play a crucial role in the activation 
of extracellular antigens (39). 
 Rab27A is associated with invasive and metastatic potential of human breast cancer 
cell development. The over expression of Rab27A protein redistributed the cell cycle and 
increased the invasive and metastatic abilities in breast cancer cells both in vitro and in vivo. 
We also certified that Rab27A bestowed the invasive and metastatic phenotypes on breast 
cancer cells by promoting the secretion of insulin-like growth factor-II (IGF-II), which 
regulates the expression of p16, vascular endothelial growth factor, matrix meta- 
metalloproteinase-9, cathepsin D, cyclin D1, and urokinase-type plasminogen activator. The 
data provides functional evidence that Rab27A acts as a novel mediator of invasion and 
metastasis promotion in human breast cancer cells, at least in part, through regulating the 
secretion of IGF-II, suggesting that synergistic suppression of Rab27A and IGF-II activities 
holds a promise for preventing breast cancer invasion and metastasis (40). 
 The signaling and in vitro phenotypic consequences of Rab11a expression and 
function were studied. Transfection of DN-Rab11a increased Erk1/2 activation downstream 
of EGF, but exerted no effect on the AKT pathway. Expression of DN-Rab11a inhibited 
MCF10A proliferation by 50-60%, and also inhibited anchorage-dependent colonization. 
Notably, DN-Rab11a transfection increased motility toward EGFR ligands. The data provides 
a first demonstration that Rab11a modulates EGFR recycling, and promotes the proliferation 
but inhibits the motility of an immortal breast line, consistent with the DCIS phenotype (41).  
 Once candidate genes are identified, we perform functional genomics by manipulating 
levels in normal and tumor cells using RNAi or transfection, and assessing a battery of 
cellular functions including proliferation, anti-apoptosis, loss of contact inhibition, changes in 
cell signaling or transcriptional profiles, anchorage-independent growth, and in vivo tumor 
growth. We have successfully used this approach to identify the RAB25 gene that has been 
implicated in the progression and aggressiveness of ovarian and breast cancers (42). 
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 Important processes in which RAB participate are in many points convergent by 
interaction with paclitaxel. Cooperation of paclitaxel with RAB proteins seemed to be the 
opposite in the majority of points. Additionally paclitaxel in self-induction process activate 
excessive transcription and increase production activity of the RAB gene. It suggests 
development of effective resistance on applied drug in the positive feedback loop 
mechanism. Another aspect is external antigen induction by RAB proteins. It brings a 
conclusion that the RAB gene can be an indicator of cancer cell sensitivity on different 
schemes of cytostatic treatment. Additionally because RAB increases neoplasm antigen 
activity, it is possible to estimate changes in expression level of this gene which can be early 
manifestation of neoplasm development.  
 In conclusion it should be stated that paclitaxel influenced cancer cells in different 
ways. On one hand the main activity is concerned with activation of apoptosis and stopping 
cell division in G2/M cell cycle. On the other hand, increased resistance for this treatment is 
manifested by a significant increase of expression level of oncogenes. It seemed that in 
estimation response for cytostatic treatment it is dependent on answering a question which of 
these ways play a crucial role in development of persistent resistance.  
 RAB25 is likely to be an important factor in breast cancer development. RAB25 could 
be used as biological marker of breast cancer and provides a target for gene replacement 
therapy.  
 Changes correlated with a worsened outcome in both diseases. In addition, enforced 
expression of RAB25 in both breast and ovarian cancer cells decreased apoptosis and 
increased proliferation and aggressiveness in vivo, potentially explaining the worsened 
prognosis. A better understanding of genetic alterations as well as the physiologic and 
pathophysiologic roles of RAB GTPases may open new opportunities for therapeutic 
intervention and better outcomes. 
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